Raymond James analyst Steven Seedhouse maintained a Buy rating on Apellis Pharmaceuticals (APLS) yesterday. The company’s shares closed last Friday at $44.26.
According to TipRanks.com, Seedhouse is a 3-star analyst with an average return of 6.4% and a 39.7% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Alexion Pharmaceuticals, and NGM Biopharmaceuticals.
Currently, the analyst consensus on Apellis Pharmaceuticals is a Strong Buy with an average price target of $70.89, which is a 56.2% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Apellis Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $184 million. In comparison, last year the company had a GAAP net loss of $169 million.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
